Literature DB >> 19552894

Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.

Philippe O Gannon1, Alexis O Poisson, Nathalie Delvoye, Réjean Lapointe, Anne-Marie Mes-Masson, Fred Saad.   

Abstract

INTRODUCTION: Our goal was to study the hormonal regulation of immune cell infiltration in prostate cancer patients treated by androgen deprivation therapy (ADT) using an optimized computer-assistance quantification approach.
METHODS: The relative density of immune cell subtypes (CD3(+), CD8(+), CD20(+), CD56(+), CD68(+) and Foxp3(+)) was analyzed by immunohistochemistry in archived prostate specimens from control patients (radical prostatectomy only, n=40) and ADT-treated patients (ADT prior to radical prostatectomy, n=35) using an image analysis software and a whole-slide scanner.
RESULTS: ADT-treated patients had significantly increased relative density of CD3(+) (p<0.001) and CD8(+) T lymphocytes (p<0.001) as well as CD68(+) macrophages (p<0.001). Elevated abundance of CD56(+) Natural Killer (NK) cells was associated with a lower risk of prostate cancer progression (p=0.044), while a high density of CD68(+) macrophages was related to an increased risk of biochemical recurrence (p=0.011).
CONCLUSIONS: Our results demonstrate that the infiltration of specific immune cell subtypes is modulated by ADT. Furthermore our data confirm that NK cells have a protective role against tumor progression while macrophages seem to favor the development of advanced prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19552894     DOI: 10.1016/j.jim.2009.06.004

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  108 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

2.  NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.

Authors:  Sylvie Rusakiewicz; Aurélie Perier; Michaela Semeraro; Jonathan M Pitt; Elke Pogge von Strandmann; Katrin S Reiners; Sandrine Aspeslagh; Christelle Pipéroglou; Frédéric Vély; Alexandre Ivagnes; Sarah Jegou; Niels Halama; Loic Chaigneau; Pierre Validire; Christos Christidis; Thierry Perniceni; Bruno Landi; Anne Berger; Nicolas Isambert; Julien Domont; Sylvie Bonvalot; Philippe Terrier; Julien Adam; Jean-Michel Coindre; Jean-François Emile; Vichnou Poirier-Colame; Kariman Chaba; Benedita Rocha; Anne Caignard; Antoine Toubert; David Enot; Joachim Koch; Aurélien Marabelle; Marion Lambert; Sophie Caillat-Zucman; Serge Leyvraz; Christian Auclair; Eric Vivier; Alexander Eggermont; Christophe Borg; Jean-Yves Blay; Axel Le Cesne; Olivier Mir; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

3.  Elimination of CD4lowHLA-G+ T cells overcomes castration-resistance in prostate cancer therapy.

Authors:  Chao Wang; Jiahuan Chen; Qianfei Zhang; Wang Li; Shengbo Zhang; Yanjie Xu; Fang Wang; Bing Zhang; Yan Zhang; Wei-Qiang Gao
Journal:  Cell Res       Date:  2018-10-08       Impact factor: 25.617

Review 4.  Innate and acquired immune surveillance in the postdissemination phase of metastasis.

Authors:  Hugo Gonzalez; Isabella Robles; Zena Werb
Journal:  FEBS J       Date:  2017-11-24       Impact factor: 5.542

Review 5.  Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.

Authors:  Angela K B Alme; Beerinder S Karir; Bishoy M Faltas; Charles G Drake
Journal:  Urol Oncol       Date:  2016-02-28       Impact factor: 3.498

Review 6.  Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity.

Authors:  Caroline Jochems; Jeffrey Schlom
Journal:  Exp Biol Med (Maywood)       Date:  2011-04-12

7.  Ectopic fibroblast growth factor receptor 1 promotes inflammation by promoting nuclear factor-κB signaling in prostate cancer cells.

Authors:  Cong Wang; Yuepeng Ke; Shaoyou Liu; Sharon Pan; Ziying Liu; Hui Zhang; Zhichao Fan; Changyi Zhou; Junchen Liu; Fen Wang
Journal:  J Biol Chem       Date:  2018-08-09       Impact factor: 5.157

8.  Immunologic biomarkers in prostate cancer: the AE37 paradigm.

Authors:  Constantin N Baxevanis; Michael Papamichail; Sonia A Perez
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

9.  Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?

Authors:  Timothy E Krueger; Daniel L J Thorek; Alan K Meeker; John T Isaacs; W Nathaniel Brennen
Journal:  Prostate       Date:  2018-11-28       Impact factor: 4.104

Review 10.  Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers.

Authors:  Irina Larionova; Gulnara Tuguzbaeva; Anastasia Ponomaryova; Marina Stakheyeva; Nadezhda Cherdyntseva; Valentin Pavlov; Evgeniy Choinzonov; Julia Kzhyshkowska
Journal:  Front Oncol       Date:  2020-10-22       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.